Member Profile

Acepodia Inc. (hereinafter referred to as Acepodia), was co-founded by Dr. Patrick Y. Yang and Dr. Sonny Hsiao in February 2017. Dr. Yang, the Chairman of the company, has held key positions such as Global Head of Technical Operations at Roche, Vice President and Deputy General Manager at Genentech, and Merck & Co. He possesses decades of multinational pharmaceutical management experience. Dr. Sonny Hsiao, the CEO, is a young entrepreneur and the inventor of the company’s core technology, Antibody-Cell Conjugation (ACC). This technology is derived from the Nobel Prize-winning research in the field of click chemistry by Professor Carolyn Bertozzi at Stanford University. Acepodia also has a seasoned industry expert, Dr. Harry Lam, a Biologics Manufacturing expert who worked at Genentech, Inc. and Sanofi S.A., serving as the Chief Technology Officer.

Acepodia focuses on developing next-generation cell-based immunotherapies for unmet medical needs in solid tumors and hematologic cancers. By leveraging the ACC technology platform and combining it with its proprietary intellectual property, Acepodia has developed a series of antibody-conjugated effector cell (ACE) therapeutic products using δγ2T cells and oNK cells. These products are designed as “allogeneic” and “off-the-shelf” cell therapy products. Acepodia’s most advanced cell therapy candidates are ACE1831 (δγ2T cells conjugated with CD20 antibody for the treatment of hematologic tumors) and ACE1702 (oNK cells conjugated with HER2 antibody for the treatment of solid tumors). Both candidates have received IND approval from regulatory authorities in Taiwan and the United States to proceed with Phase I clinical trials.